Forecasting Biopharma's Financial Future

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

If you were to ask biopharmaceutical executives, “What are the annual can’t-miss meetings?” I’d wager the one most frequently mentioned would be the annual J.P. Morgan Healthcare Conference (JPM). Taking place every January in San Francisco, JPM is like our industry’s annual kickoff. As such, it draws thousands of biopharma execs, and the dozen or so satellite conferences that surround it have become important in their own right. Because, although JPM draws many of industry’s heavy hitters, shows like Biotech Showcase (BTS) support those companies just getting started or, as I like to think about them, the future Regenerons of our industry. In fact, if you think about it, three of our industry’s biggest events (i.e., JPM, BTS, and the BIO CEO & Investors Conference) happen within the first two months of the year — and each of them focuses on more of the financial aspects of our industry. Thus, it made sense that our annual outlook issue should include information from a collection of biopharma financial experts. So, let’s get started.